Understanding the Potential and Risk of Bacterial Siderophores in Cancer
Open Access
- 17 June 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 867271
Abstract
Siderophores are iron chelating molecules produced by nearly all organisms, most notably by bacteria, to efficiently sequester the limited iron that is available in the environment. Siderophores are an essential component of mammalian iron homeostasis and the ongoing interspecies competition for iron. Bacteria produce a broad repertoire of siderophores with a canonical role in iron chelation and the capacity to perform versatile functions such as interacting with other microbes and the host immune system. Siderophores are a vast area of untapped potential in the field of cancer research because cancer cells demand increased iron concentrations to sustain rapid proliferation. Studies investigating siderophores as therapeutics in cancer generally focused on the role of a few siderophores as iron chelators; however, these studies are limited and some show conflicting results. Moreover, siderophores are biologically conserved, structurally diverse molecules that perform additional functions related to iron chelation. Siderophores also have a role in inflammation due to their iron acquisition and chelation properties. These diverse functions may contribute to both risks and benefits as therapeutic agents in cancer. The potential of siderophore-mediated iron and bacterial modulation to be used in the treatment of cancer warrants further investigation. This review discusses the wide range of bacterial siderophore functions and their utilization in cancer treatment to further expand their functional relevance in cancer detection and treatment.Keywords
Funding Information
- Ohio State University
This publication has 216 references indexed in Scilit:
- The siderophore yersiniabactin binds copper to protect pathogens during infectionNature Chemical Biology, 2012
- Siderophore-mediated iron trafficking in humans is regulated by ironJournal of Molecular Medicine, 2012
- A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE -Related Hereditary HemochromatosisHepatology, 2010
- Iron traffics in circulation bound to a siderocalin (Ngal)–catechol complexNature Chemical Biology, 2010
- A Mammalian Siderophore Synthesized by an Enzyme with a Bacterial Homolog Involved in Enterobactin ProductionCell, 2010
- Sideromycins: tools and antibioticsBioMetals, 2009
- Correlation between virulence factors and in vitro biofilm formation by Escherichia coli strainsMicrobial Pathogenesis, 2008
- Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overloadInternational Journal of Hematology, 2008
- A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeuticsProceedings of the National Academy of Sciences, 2006
- Neutrophil Gelatinase-associated Lipocalin, a Siderophore-binding Eukaryotic ProteinBioMetals, 2006